K Hovnanian Children’s Hospital at Jersey Shore University Medical Center, and Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital ranking nationally for ...
NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...
Bristol Myers Squibb. “This is the first and only Phase 3 study of a neoadjuvant-only immuno-oncology therapy to show a statistically significant benefit in patients with resectable NSCLC.” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback